Stocktoria
Aurobindo Pharma Limited AUROPHARMA.NS
Aurobindo Pharma Limited statistics & valuation
Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value (₹945.55); a green figure means the price is below it.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
P / E vs its own history
Aurobindo Pharma Limited trades at about 28.1× earnings — above its 10-year norm (10-year range 18.8×–23×, median 21.3×).
Shaded band = 10-year range (18.8×–23×); dot = today's 28.1×.
Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.
Key ratios (by fiscal year)
| Ratio | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Gross margin | 57.1% | 56.2% | 53.9% | 51.7% |
| Operating margin | 15.6% | 16.1% | 15.5% | 10.3% |
| Net margin | 10.5% | 11.1% | 11.1% | 7.8% |
| FCF margin | 7.3% | 4.5% | -3.9% | -1.4% |
| Return on assets | 6.0% | 7.0% | 7.0% | 4.8% |
| Return on equity | 9.2% | 10.7% | 10.6% | 7.2% |
| Debt / equity | 0.02× | 0.05× | 0.07× | 0.02× |
| Current ratio | 1.81 | 1.85 | 1.98 | 1.87 |
Computed from company filings · IN · as of 2026-03-31. Figures in INR. Facts plus Stocktoria's own computed scores — not investment advice.